Michael E. Thase, MD

Corporal Michael J Cresencz VAMC, Philadelphia, Pennsylvania; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

  • 183Articles
  • 767.4KReads
  • 1997–2026Active
  • 421Collaborators
  • 3.7KCitations

About

Michael E. Thase, MD, is affiliated with the Corporal Michael J Cresencz VAMC and the Department of Psychiatry at the Perelman School of Medicine, University of Pennsylvania. His extensive publication record since 1997 includes research on major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorders, neurology, psychiatry, psychopharmacology, patient care, and suicide. His work addresses topics such as antidepressant treatment effects, cognitive behavioral therapy for relapse prevention, treatment-resistant depression, deprescribing, and patient functioning and life engagement across psychiatric conditions. Dr. Thase has frequently collaborated with Madhukar H. Trivedi, A. John Rush, Maurizio Fava, Martin B. Keller, and Andrew A. Nierenberg.

Publications

JCP
When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?
ASCP Corner

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...
, , , et al
JCP
CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial
Original Research

CBT following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial

May 4, 2026

In patients with major depression and suicidal ideation, adding a 16-week CBT course to esketamine led to greater improvements in suicidal ideation and depression severity than esketamine alone.
, , , et al
JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?
ASCP Corner

What Is Meant by the Term “Deprescribing,” and Does It Belong in Our Lexicon?

June 2, 2025

The authors encourage the field to destigmatize the term “deprescribing” from its misappropriated usage, explicate its accurate definition, and reclaim its purposeful meaning.
, , , et al
JCP
Developments in Major Depressive Disorder Therapy
Educational Activity

Developments in Major Depressive Disorder Therapy

August 14, 2023

Among the greatest unmet needs in MDD is for effective pharmacotherapies for patients who do not respond to first- and second-line antidepressant medications. After decades of muted progress, alternatives...
PCC
Screening for Bipolar Disorder and Evaluating the RMS
Original Research

Screening for Bipolar Disorder and Evaluating the RMS

April 25, 2023

Health care providers found the Rapid Mood Screener, a new bipolar I disorder screening tool, to be superior to the widely used Mood Disorder Questionnaire in sensitivity/specificity, brevity, practicality,...
, , , et al
JCP
Patient Functioning and Life Engagement: Treatment Goals in MDD
Insights

Patient Functioning and Life Engagement: Treatment Goals in MDD

September 7, 2022

Patients with MDD often report lack of motivation and energy and a feeling of disengagement from their own lives. Here, experts discuss treatment strategies that may be favorable for...
, , , et al
JCP
Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder
Academic Highlights

Patient Functioning, Life Engagement, and Treatment Goals in Major Depressive Disorder

September 7, 2022

Patients with MDD often report lack of motivation and energy and a feeling of disengagement from their own lives. Here, experts discuss treatment strategies that may be favorable for...
, , , et al
JCP
Patient Functioning and Life Engagement: Treatment Goals in Schizophrenia
Insights

Patient Functioning and Life Engagement: Treatment Goals in Schizophrenia

August 17, 2022

Many people with schizophrenia feel isolated and disengaged from their own lives even when symptoms are under control. Here, experts discuss assessment of life engagement and treatment strategies that...
, , , et al
JCP
Patient Functioning, Life Engagement, and Treatment Goals in Schizophrenia
Academic Highlights

Patient Functioning, Life Engagement, and Treatment Goals in Schizophrenia

August 17, 2022

Many people with schizophrenia feel isolated and disengaged from their own lives even when symptoms are under control. Here, experts discuss assessment of life engagement and treatment strategies that...
, , , et al
JCP
Patient Functioning and Life Engagement: Unmet Needs in MDD and Schizophrenia
Insights

Patient Functioning and Life Engagement: Unmet Needs in MDD and Schizophrenia

August 8, 2022

Besides achieving symptom relief and improved functioning, many patients with serious mental illness wish to connect more with others and feel engaged with their lives. Five experts discuss life...
, , , et al
JCP
Patient Functioning and Life Engagement: Unmet Needs in MDD and Schizophrenia
Academic Highlights

Patient Functioning and Life Engagement: Unmet Needs in MDD and Schizophrenia

August 3, 2022

Besides achieving symptom relief and improved functioning, many patients with serious mental illness wish to connect more with others and feel engaged with their lives. Five experts discuss life...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe